Clinical Trial Update: Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency

View source ↗

Summary

A trial evaluating niraparib versus bevacizumab as maintenance therapy in patients with de novo ovarian cancer without homologous recombination deficiency; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Zejula (Niraparib)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Ovarian Carcinoma | Status: RECRUITING